Please use this identifier to cite or link to this item:
Title: Carbimazole-induced agranulocytosis: does antineutrophil cytoplasmic antibody have a role?
Austin Authors: Yip, G;Ekinci, Elif I ;Lee, S T;Jerums, George ;Grossmann, Mathis 
Affiliation: Department of Medicine, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 1-Apr-2010
Publication information: Internal Medicine Journal; 40(4): 300-3
Abstract: Carbimazole is a drug that is widely used for hyperthyroid disorders, such as Graves' disease. Agranulocytosis is a rare idiosyncratic adverse reaction to the drug which is potentially fatal. This report describes a patient with a history of successfully treated pyoderma gangrenosum, who developed agranulocytosis 3 weeks after commencement of carbimazole for Graves' disease. It may give credence to the theory that implicates antineutrophil cytoplasmic antibodies in the pathogenesis of agranulocytosis induced by antithyroid drugs.
Gov't Doc #: 20529040
DOI: 10.1111/j.1445-5994.2009.02143.x
Type: Journal Article
Subjects: Adult
Agranulocytosis.chemically induced.diagnosis.immunology
Antibodies, Antineutrophil Cytoplasmic.biosynthesis.blood.physiology
Carbimazole.adverse effects
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 7, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.